These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 34432318

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Expression of Th17 and IL-23 in Peripheral Blood and Their Relationship with Immunophenotype in Patients with Acute Myeloid Leukemia].
    Peng ZY, Yang CX, San JH, Li QQ, Zhang MM, Shi B.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1056-1062. PubMed ID: 35981362
    [Abstract] [Full Text] [Related]

  • 5. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
    Appelbaum FR.
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Socié G, Ljungman P, Huynh A, Deconinck E, Wu D, Bourhis JH, Cahn JY, Polge E, Mohty M, Savani BN, Nagler A.
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [Abstract] [Full Text] [Related]

  • 8. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A, De Marchi F, Zannier ME, Lazzarotto D, Filì C, Dubbini MV, Rabassi N, Toffoletti E, Lau BW, Fanin R.
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [Abstract] [Full Text] [Related]

  • 9. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.
    Norkin M, Katragadda L, Zou F, Xiong S, Chang M, Dai Y, Hsu JW, Moreb JS, Leather H, Murthy HS, Farhadfar N, Li Y, Hromas R, Brown RA, Cogle CR, Wingard JR.
    Blood Cancer J; 2017 Nov 27; 7(12):634. PubMed ID: 29176662
    [Abstract] [Full Text] [Related]

  • 10. Impact of pre-transplant disease burden on the outcome of allogeneic hematopoietic stem cell transplant in refractory and relapsed acute myeloid leukemia: a single-center study.
    Tian H, Chen GH, Xu Y, Ma X, Chen F, Yang Z, Jin ZM, Qiu HY, Sun AN, Wu DP.
    Leuk Lymphoma; 2015 May 27; 56(5):1353-61. PubMed ID: 25204372
    [Abstract] [Full Text] [Related]

  • 11. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
    Liu YR, Wang YZ, Chen SS, Chang Y, Fu JY, Li LD, Wang H, Yu H, Jiang B, Huang XJ.
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov 27; 28(11):731-6. PubMed ID: 18457262
    [Abstract] [Full Text] [Related]

  • 12. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.
    Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, Estey EH, Salter AI, Lansverk E, Chien JW, Gopal AK, Appelbaum FR, Pagel JM.
    J Clin Oncol; 2011 Mar 20; 29(9):1190-7. PubMed ID: 21282535
    [Abstract] [Full Text] [Related]

  • 13. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
    Zhao H, Wei J, Wei G, Luo Y, Shi J, Cui Q, Zhao M, Liang A, Zhang Q, Yang J, Li X, Chen J, Song X, Jing H, Li Y, Hao S, Wu W, Tan Y, Yu J, Zhao Y, Lai X, Yin ETS, Wei Y, Li P, Huang J, Wang T, Blaise D, Xiao L, Chang AH, Nagler A, Mohty M, Huang H, Hu Y.
    J Hematol Oncol; 2020 May 04; 13(1):42. PubMed ID: 32366260
    [Abstract] [Full Text] [Related]

  • 14. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
    Yan CH, Liu QF, Wu DP, Zhang X, Xu LP, Zhang XH, Wang Y, Huang H, Bai H, Huang F, Ma X, Huang XJ.
    Biol Blood Marrow Transplant; 2017 Aug 04; 23(8):1311-1319. PubMed ID: 28483716
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of lymphoid marker CD7 expression in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in first morphological complete remission.
    Lv K, Cai C, Chen J, Xu M, Wan L, Zhou M, Du Y, Ma X, Wu X, Tang X, Qiu H, Wu D, Han Y, Liu Y.
    Int J Hematol; 2021 Oct 04; 114(4):464-471. PubMed ID: 34176091
    [Abstract] [Full Text] [Related]

  • 16. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
    Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, Mielcarek M, Estey EH, Appelbaum FR, Walter RB.
    J Clin Oncol; 2016 Feb 01; 34(4):329-36. PubMed ID: 26668349
    [Abstract] [Full Text] [Related]

  • 17. Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression.
    Xiaosu Z, Leqing C, Yazhen Q, Yu W, Xiaohui Z, Lanping X, Xiaojun H, Yingjun C.
    Ann Hematol; 2019 Jan 01; 98(1):73-81. PubMed ID: 30159599
    [Abstract] [Full Text] [Related]

  • 18. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS, Hu YL, Guan LX, Peng B, Wang SY.
    Hematology; 2021 Dec 01; 26(1):179-185. PubMed ID: 33594943
    [Abstract] [Full Text] [Related]

  • 19. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z, Guo M, Zhang Y, Xu S, Cheng H, Wu J, Zhang W, Hu X, Yang J, Wang J, Tang G.
    Int J Lab Hematol; 2019 Oct 01; 41(5):607-614. PubMed ID: 31162830
    [Abstract] [Full Text] [Related]

  • 20. Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.
    Mo XD, Wang Y, Zhang XH, Xu LP, Yan CH, Chen H, Chen YH, Qin YZ, Liu KY, Huang XJ.
    Oncologist; 2018 Nov 01; 23(11):1349-1357. PubMed ID: 30076280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.